Skip to content

Lymphocyte Counts in Immune Thrombocytopenic Purpura

Initial Lymphocyte Counts Predictive Value in Immune Thrombocytopenic Purpura

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03244410
Enrollment
1
Registered
2017-08-09
Start date
2017-10-31
Completion date
2019-01-31
Last updated
2017-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenic Purpura

Brief summary

* immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number (cooper N et al 2006) * recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( cooper N et al 2006) ( Gern Sheimer T 2009 )

Detailed description

Immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number ( Cooper N et all 2006) platelet surface membrane proteins become antigenic for unknown reasons, leading to stimulation of the immune system, auto antibodies production and platelet destruction ( Gasbarrini A et all 2000) It is associated with the production of auto antibodies directed against platelet glycoprotein complex 2b/3a and/or 1b/1x , resulting in accelerated destruction of platelets by the reticular endothelial system via the activity of Fcc receptor bearing phagocytic cells ( Provan & Newland et al 2002) Recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( Cooper N et al 2006) ( Gern Sheimer T 2009) There are many phases of the disease: 1. Newly diagnosed ITP : for all cases at diagnosis. 2. persistent ITP: for patients with ITP between 3 to 12 months. 3. chronic ITP: for patients with ITP lasting more than one year ( blood journal 2009). * Although lymphocytopenia is a commonly reported feature of many chronic autoimmune disorders, differential white cell counts at presentation have seldom been evaluated as predictors for development of chronic ITP ( Deel MD et al 2013) (Ahmed et al 2010)

Interventions

DIAGNOSTIC_TESTcomplete blood picture

complete blood picture

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Newly diagnosed cases of primary ITP , adults and children.

Exclusion criteria

* Cases of secondary ITP

Design outcomes

Primary

MeasureTime frameDescription
lymphocyte count in immune thrombocytopenic purpura15 minutesintital lymphocyte counts predictive value in immune thrombocytopenic purpura by complete blood picture

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026